Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 5:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 513 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Infection, Human Immunodeficiency Virus I Clear all
Completed Phase 1 Interventional

A Study of the Safety and Effectiveness of a Chickenpox Vaccine in HIV-Infected Children

NCT00000837
View directory record Official record
Conditions
HIV Infections
Interventions
Varicella Virus Vaccine (Live)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Months to 8 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
25
States / cities
Long Beach, California • Los Angeles, California • Oakland, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 13, 2026, 5:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

GSK706769/KALETRA Drug-drug Interaction Study

NCT00723775
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK706769 & KALETRA
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 13, 2026, 5:01 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety, Tolerability and Immune Response to LC002, an Experimental Therapeutic Vaccine, in Adults Receiving HAART

NCT00270205
View directory record Official record
Conditions
HIV Infections
Interventions
LC002 standard vaccination, LC002 high-dose vaccination, LC002 placebo vaccination
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
5
States / cities
Sacramento, California • Chicago, Illinois • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 13, 2026, 5:01 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Botswana Study of UC-781 Vaginal Microbicide

NCT00385554
View directory record Official record
Conditions
HIV Infections
Interventions
UC-781 carbomer gel, 0.1% and 0.25%
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
21 Years to 45 Years
Healthy volunteers
Accepts healthy volunteers
U.S. locations
2
States / cities
Atlanta, Georgia • Arlington, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 16, 2012 · Synced Oct 13, 2026, 5:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Safety and Immunogenicity Trial of HIV-1 gp120 C4-V3 Hybrid Polyvalent Peptide Immunogen Mixed in Mineral Oil Containing Mannose Mono-Oleate (IFA)

NCT00000886
View directory record Official record
Conditions
HIV Infections
Interventions
HIV-1 C4-V3 Polyvalent Peptide Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1999
U.S. locations
3
States / cities
Rochester, New York • Nashville, Tennessee • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 13, 2026, 5:01 PM EDT
Completed Phase 1 Interventional

A Study of Nitazoxanide in the Treatment of AIDS-Related Diarrhea

NCT00002444
View directory record Official record
Conditions
HIV Infections
Interventions
Nitazoxanide
Drug
Lead sponsor
Unimed Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 1996
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 13, 2026, 5:01 PM EDT
Completed Phase 1 Interventional

HIV-1 Specific T -Cells (HST-NEETs) for HIV-Infected Individuals

NCT03485963
View directory record Official record
Conditions
HIV Infections
Interventions
HST-NEETs
Biological
Lead sponsor
Catherine Bollard
Other
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 13, 2026, 5:01 PM EDT
Completed Phase 1 Interventional

Phase I Study of HIV 1 Antigen Expanded Specific T Cell Therapy

NCT02208167
View directory record Official record
Conditions
HIV
Interventions
HXTC infusion
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Oct 13, 2026, 5:01 PM EDT
Completed Phase 1 Interventional

Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728 for HIV

NCT00842634
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
ZFN modified T cells, Structured Treatment Interruption
Biological · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
The Bronx, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 8, 2019 · Synced Oct 13, 2026, 5:01 PM EDT
Completed Phase 2 Interventional

Interferon Alfa in Treating Children With HIV-Related Cancer

NCT00002621
View directory record Official record
Conditions
Leukemia, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
recombinant interferon alfa
Biological
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2005
U.S. locations
7
States / cities
Wichita, Kansas • New Orleans, Louisiana • Hackensack, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Oct 13, 2026, 5:01 PM EDT
Not listed Phase 1 Interventional

A Study of Tucaresol in HIV-Infected Patients Who Are Taking Other Anti-HIV Drugs

NCT00006209
View directory record Official record
Conditions
HIV Infections
Interventions
Tucaresol
Drug
Lead sponsor
Aaron Diamond AIDS Research Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 13, 2026, 5:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immune Response Study of High-Dose Canarypox ALVAC-HIV Vaccine in Healthy, HIV Uninfected Adults

NCT00027261
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity
Interventions
ALVAC(2)120(B,MN)GNP (vCP1452)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2005
U.S. locations
13
States / cities
Birmingham, Alabama • San Francisco, California • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 13, 2026, 5:01 PM EDT
Completed Phase 1 Interventional

The Safety and Effectiveness of RMP-7 Plus Amphotericin B in Patients With HIV and Cryptococcal Meningitis

NCT00002316
View directory record Official record
Conditions
Meningitis, Cryptococcal, HIV Infections
Interventions
Lobradimil, Amphotericin B
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
11
States / cities
Los Angeles, California • Orange, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 13, 2026, 5:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioavailability Study of 10 Milligram (mg) and 5 mg Tablets Versus Conventional Tablets of Dolutegravir

NCT03095638
View directory record Official record
Conditions
HIV Infections
Interventions
Conventional dolutegravir 10 mg tablet, Conventional dolutegravir 50 mg tablet, Dispersible dolutegravir 5 mg tablet, Conventional dolutegravir 25 mg tablet
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 13, 2026, 5:01 PM EDT
Completed Phase 1 Interventional Results available

Evaluating the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody (VRC01) in HIV-Infected Adults Undergoing a Brief Treatment Interruption

NCT02463227
View directory record Official record
Conditions
HIV Infections
Interventions
VRC01
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Birmingham, Alabama • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Oct 13, 2026, 5:01 PM EDT
Completed Phase 2 Interventional Results available

Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma

NCT00392990
View directory record Official record
Conditions
Lymphoma
Interventions
Regimen A, Regimen B
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
8
States / cities
Chicago, Illinois • Maywood, Illinois • Park Ridge, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Oct 13, 2026, 5:01 PM EDT
Completed Phase 1 Interventional

A Study of BMY-27857 in Patients With AIDS or AIDS Related Complex

NCT00000988
View directory record Official record
Conditions
HIV Infections
Interventions
Stavudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 26, 2008 · Synced Oct 13, 2026, 5:01 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents

NCT00006604
View directory record Official record
Conditions
HIV Infections
Interventions
ATV, Ritonavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
91 Days to 21 Years
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2014
U.S. locations
32
States / cities
Birmingham, Alabama • Alhambra, California • La Jolla, California + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 13, 2026, 5:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate Pharmacokinetics, Safety and Tolerability of Dolutegravir and Rilpivirine (JULUCA™) 50 Milligram (mg)/25 mg Tablets in Healthy Subjects of Japanese Descent

NCT03984838
View directory record Official record
Conditions
HIV Infections
Interventions
JULUCA (Dolutegravir and Rilpivirine) 50mg/25mg FDC tablet
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Oct 13, 2026, 5:01 PM EDT
Completed Phase 1 Interventional

Safety of Recombinant HIV Vaccines in HIV Infected Young Adults on Stable Therapy

NCT00107549
View directory record Official record
Conditions
HIV Infections
Interventions
rMVA-HIV (env/gag [TBC-M358] + tat/rev/nef-RT [TBC-M335)]), rFPV-HIV (env/gag [TBC-F357] + tat/rev/nef-RT [TBC-F349])
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 24 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2009
U.S. locations
8
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 13, 2026, 5:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dolutegravir Renal Impairment Study

NCT01353716
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Dolutegravir 50 mg
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 30, 2012 · Synced Oct 13, 2026, 5:01 PM EDT
Completed Phase 1 Interventional

A Phase I/II Trial of Ribavirin (With Escalation) + Isoprinosine in Asymptomatic HIV-Viremic Patients

NCT00000699
View directory record Official record
Conditions
HIV Infections
Interventions
Inosine pranobex, Ribavirin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 26, 2008 · Synced Oct 13, 2026, 5:01 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety and Tolerance of Nelfinavir (NFV) Given With Zidovudine (ZDV) and Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants

NCT00000887
View directory record Official record
Conditions
HIV Infections, Pregnancy
Interventions
Nelfinavir mesylate, Lamivudine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
7
States / cities
Los Angeles, California • New Orleans, Louisiana • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 13, 2026, 5:01 PM EDT
Completed Phase 1 Interventional

A Phase I Study to Evaluate the Pharmacokinetics, Safety and Antiviral Effects of Concurrent Administration of Zidovudine (AZT) and 2'3'-Dideoxyinosine (ddI) in Patients With Human Immunodeficiency Virus (HIV)

NCT00002014
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Didanosine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
4
States / cities
San Francisco, California • Miami, Florida • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 13, 2026, 5:01 PM EDT